Literature DB >> 22936790

N-myc and noncoding RNAs in neuroblastoma.

Jochen Buechner1, Christer Einvik.   

Abstract

Neuroblastoma is a pediatric tumor of the sympathetic nervous system. Amplification and overexpression of the MYCN proto-oncogene occurs in approximately 20% of neuroblastomas and is associated with advanced stage disease, rapid tumor progression, and poor prognosis. MYCN encodes the transcriptional regulator N-myc, which has been shown to both up- and downregulate many target genes involved in cell cycle, DNA damage, differentiation, and apoptosis in neuroblastoma. During the last years, it has become clear that N-myc also modulates the expression of several classes of noncoding RNAs, in particular microRNAs. MicroRNAs are the most widely studied noncoding RNA molecules in neuroblastoma. They function as negative regulators of gene expression at the posttranscriptional level in diverse cellular processes. Aberrant regulation of miRNA expression has been implicated in the pathogenesis of neuroblastoma. While the N-myc protein is established as an important regulator of several miRNAs involved in neuroblastoma tumorigenesis, tumor suppressor miRNAs have also been documented to repress MYCN expression and inhibit cell proliferation of MYCN-amplified neuroblastoma cells. It is now becoming increasingly evident that N-myc also regulates the expression of long noncoding RNAs such as T-UCRs and ncRAN. This review summarizes the current knowledge about the interplay between N-myc and noncoding RNAs in neuroblastoma and how this contributes to neuroblastoma tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22936790     DOI: 10.1158/1541-7786.MCR-12-0244

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  29 in total

1.  Redefining functional MYCN gene signatures in neuroblastoma.

Authors:  Jason Matthew Shohet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-08       Impact factor: 11.205

Review 2.  The lncRNA-MYC regulatory network in cancer.

Authors:  Kaiyuan Deng; Xiaoqiang Guo; Hao Wang; Jiazeng Xia
Journal:  Tumour Biol       Date:  2014-08-20

Review 3.  Functional variomics and network perturbation: connecting genotype to phenotype in cancer.

Authors:  Song Yi; Shengda Lin; Yongsheng Li; Wei Zhao; Gordon B Mills; Nidhi Sahni
Journal:  Nat Rev Genet       Date:  2017-03-27       Impact factor: 53.242

4.  Single nucleotide polymorphism rs11669203 in TGFBR3L is associated with the risk of neuroblastoma in a Chinese population.

Authors:  Yaqiong Jin; Huanmin Wang; Wei Han; Jie Lu; Ping Chu; Shujing Han; Xin Ni; Baitang Ning; Dianke Yu; Yongli Guo
Journal:  Tumour Biol       Date:  2015-10-14

Review 5.  Role of non-coding sequence variants in cancer.

Authors:  Ekta Khurana; Yao Fu; Dimple Chakravarty; Francesca Demichelis; Mark A Rubin; Mark Gerstein
Journal:  Nat Rev Genet       Date:  2016-01-19       Impact factor: 53.242

Review 6.  Neuroblastoma: molecular pathogenesis and therapy.

Authors:  Chrystal U Louis; Jason M Shohet
Journal:  Annu Rev Med       Date:  2014-10-27       Impact factor: 13.739

7.  MYCN Silencing by RNAi Induces Neurogenesis and Suppresses Proliferation in Models of Neuroblastoma with Resistance to Retinoic Acid.

Authors:  Ruhina Maeshima; Dale Moulding; Andrew W Stoker; Stephen L Hart
Journal:  Nucleic Acid Ther       Date:  2020-04-02       Impact factor: 5.486

8.  Downregulation of tumor suppressor menin by miR-421 promotes proliferation and migration of neuroblastoma.

Authors:  Yu Li; Wei Li; Jian-Guo Zhang; Hai-Yang Li; Yong-Ming Li
Journal:  Tumour Biol       Date:  2014-07-11

Review 9.  PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.

Authors:  Palanisamy Nallasamy; Srinivas Chava; Sumit S Verma; Shruti Mishra; Santhi Gorantla; Don W Coulter; Siddappa N Byrareddy; Surinder K Batra; Subash C Gupta; Kishore B Challagundla
Journal:  Semin Cancer Biol       Date:  2017-11-28       Impact factor: 15.707

Review 10.  Neuroblastoma and MYCN.

Authors:  Miller Huang; William A Weiss
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.